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We report a case of successful treatment of acquired factor VIII inhibitor after extensive 
visceral surgery. A 71-yr-old man who operated for bile duct cancer had active bleeding 
in the abdominal drainage tube on postoperative day (POD) 5, and prolonged aPTT was 
detected (83.1s) on POD 7. Extensive coagulation work up revealed Factor VIII 
deficiency (1%), diagnosis of an acquired Factor VIII deficiency was established when 
a factor VIII inhibitor of 8 Bethesda units was demonstrated. Patient treated with 
activated prothrombin complex concentrate ( aPCCs ) bloody discharge was stopped 
within three days. Inhibitor elimination was started using prednisolone ( PSL ) on POD 
20, rituximab; was administered on POD 74 and 81. Factor VIII inhibitor was 
disappeared until POD 124, Factor VIII (72%) and aPTT recovered to 45.9s. This case 
report could show usefulness of aPCCs and Rituximub in the treatment of acquired 
hemophilia associated with visceral surgery. 
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INTRODUCTION 
Acquired hemophilia A (: AHA) is one of the serious hemorrhagic disorder due to 
autoantibodies against coagulation factor VIII
1),2)
.  However, the incidence of this rare 
disease is approximately 1.5 cases/million/year, we still don’t know much about the 
mechanism. 
In many cases, it developed with a malignancy, autoimmune disease or surgery, and 
somehow associated with elderly person
1) - 3)
. While unusual postoperative bleeding was 
detected and an unexplained isolated prolonged aPTT suggest the diagnosis of acquired 
hemophilia A, and prompt further investigation, is indicated. Fatal bleeding like this 
disease should be controlled for patient even in perioperative period. Some bypassing 
agents, such as recombinant activated FVII or activated pro-thrombin complex 
concentrate
4) - 6) 
are the first choice. In addition, subsequent immunosuppressive therapy 
is necessary for autoantibody eradication. Corticosteroids or combination therapy with 
cyclophosphamide has been recommended as initial treatment, however, postoperative 
infection disease and delayed wound healing were difficult complications
7)
. Recently, 
rituximab, a monoclonal chimeric antibody to the CD 20 antigen, has also shown to be 
effective to factor VIII inhibitor autoantibody eradication
7) - 9)
.
Here, we report a case of successful treatment of acquired factor VIII inhibitor, using 
bypassing agent and corticosteroids with rituximab, after extensive visceral surgery. 
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CASE REPORT 
A 71-yr-old man presented with jaundice and skin itching without a history of 
haemophilia or previous bleeding symptom. Computed tomography (CT) and nuclear 
magnetic resonance imaging (MRI) revealed dilated common bile duct was obstructed 
at pancreatic portion by tumor (Fig. 1). Rapidly, endoscopic retrograde biliary drainage 
was performed, and then laboratory data became normal. On 7
th
 day before surgery, 
acute obstructive cholangitis was occurred due to the drainage tube trouble. Primary 
drainage tube was removed, and endoscopic nasal biliary drainage tube was inserted to 
treat cholangitis, for better drainage. He recovered from septic state, but prolonged 
activated partial thromboplastin time (aPTT: 54.3s) was remained which is predictive 
parameter of acquired haemophilia (Fig. 2). His past medical history revealed 
hypertension, angina pectoris, moyamoya disease, diabetes mellitus, and phyothrax. 
These diseases were well controled, and he was physically active. Therefore, radical 
pancreaticoduodenectomy was performed for bile duct cancer. Perioperative blood loss 
was 330ml. Doripenem and micafungin were used for preventive treatment, 0.25mg 
twice a day and 50 mg once a day, respectively. On postoperative day (POD) 5, active 
bloody discharge was found from the abdominal drainage tube which was placed around 
intestinal anastomosis. The amylase level of the drain discharge was 16 IU/l and 
bacterial culture revealed little amount of candida. Prolonged aPTT was getting worse, 
83.1s on POD 7 , erythrocyte concentrate and flesh frozen plasma were transfused for 
progressive anemia (hemoglobin 6.2 mg/dl ). CT scan could not detect bleeding point or 
pseudoaneurisum. On POD 10, leakage of gastro-jejunosotomy was noticed, bloody 
discharge still continued. On POD 14, aPTT has reached 126s we consulted hematology 
staff (Fig. 2). Detailed coagulation work up revealed Factor VIII deficiency (1%), 
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diagnosis of an acquired Factor VIII deficiency was established when a factor VIII 
inhibitor of 8 Bethesda units was demonstrated (Table. 1). Patient treated with activated 
prothrombin complex concentrate (aPCC; FEIBA [Factor VIII bypassing activity ], 
Vienna, Austria) at a dose of 50 units/kg twice daily, thereafter, bloody discharge was 
stopped within three days. After urgent anti-hemorrhagic treatment, inhibitor 
elimination was started using prednisolone ( PSL 1mg/kg/day) on POD 20. Active 
bleeding hasn’t seen, however, an enterocutaneous fistula had developed at 
gastro-jejunostomy. To acceralate wound healing PSL was tapered to 0.5mg/kg/day on 
POD 30. However, aPTT was still prolonged subcutaneous and intramuscular hematoma 
which produced severe continuous pain, have developed on POD 37. FEIBA was 
administered at the same dose for three days, and hematomas were disappeared 
eventually (Fig. 3). On POD 50 central vein catheter was infected and removed 
immediately, but aPTT elongation was reboosted by this event. As Factor VIII inhibitor 
elimination therapy, rituximab (375mg/m2), and a monoclonal chimeric antibody to the 
CD 20 antigen was administered on POD 74. Another rituximab was added on POD 81, 
from POD 86 PSL was reduced by half for a week, finally stopped on POD 120. Factor 
VIII inhibitor was disappeared until POD 124, Factor VIII (72%) and aPTT (45.9s) 
recovered to normal level (Table. 1, Fig. 2). On POD 137 enterocutaneous fistula closed 
finally, thereafter, oral intake had started, general condition was getting better and better. 
So, we recommended to him and his family to have another admission of several 
months in the nearest hospital, and then he moved on POD 187. 
DISCUSSION 
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Some factors are related to production of the inhibitor autoantibody, systemic 
autoimmune disease such as RA and SLE but may develop with a drug and a 
malignancy, the pregnancy or an operation
1) - 3)
. In our case, preoperative cholangitis and 
some antibiotics might be the first etiology and invasive surgery for cancer might be 
another. As Kreuter reported a case of acquired haemophilia in a patient with 
gram-negative urosepsis and bladder cancer, infectious disease might produce acquired 
inhibitor antibody
10)
. It is very important to make an immediate diagnosis and to start 
appropriate treatment as soon as possible, but postoperative condition is sometimes 
complicated. It might be difficult to discriminate between this disease and other 
coagulopathy such as disseminated intravascular coagulation
11)
. Three important clinical 
findings for a diagnosis are significantly prolonged aPTTs, decreasing factor VIII 
activity, and the titer measurement of the factor VIII autoantibody which is the proof of 
inhibitor existence by the Bethesda method. Once clinical diagnosis of AHA is 
confirmed before surgery, any operation shouldn’t be indicated
8)
. If inhibitor 
autoantibody is removed appropriately, any operation can be performed safely as usual
9)
. 
In our case, diagnosis of hemophilia was confirmed after postoperative bleeding, but we 
could start hematological screening even at the time point of first aPTT rise predictively, 
and this kind of delay make it sometimes life-threatening. In such a case, primary 
hemostasis must be first priority. Extremely high titer inhibitor antibody doesn’t respond 
to the factor VIII replacement therapy, activated prothrombin complex concentrates 
(aPCCs) or recombinant activated FVII (rFVIIa) has to be used for bypassing therapy
4) - 
-6)
. Actually, approximately 80% of post-operative bleeding caused by inhibitor antibody 
was controllable with aPCCs or rFVIIa, sometime different responses to therapy might be 
seen in each patient. Once bleeding episode which is non-responsive to bypassing 
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therapy was confirmed, we should switch to another agent. In this case, we used aPCCs 
first because we just had this in our hospital. 
Serious adverse effects of these treatments include DVT, myocardial infarction, and 
cerebral infarction by the clot formation, but the frequency of adverse effect is not so 
high. Fortunately, our patient didn’t have any complication like angina and cerebral 
infarction. Therefore, primary hemostasis was made successfully. For the next step, 
autoantibody removal is necessary to restore normal hemostasis condition. 
Immunosuppressive therapy should be continuing until remission was achieved. 
Corticosteroids which have been used for treatment of acquired hemophilia for long 
time, could wipe off autoantibody in one-third of cases in 3-6 weeks by giving 
1mg/kg/day. If remission was not achieved by steroids alone, combination therapy with 
cyclophosphamide should be provided. Seventy percent of remission rate was reported 
in the literature
7)
, combination therapy is recommended as first choice. Recently, 
antiCD20 antibody (Rituximub) which decrease B cell’s activity selectively, was known 
to be effective for the treatment of the autoimmune disease such as ITP or AIHA that 




Remission rate is high (77%), and it is listed as a recommendation because antibody 
depression last until complete remission. So far, we could not conclude which is better 
without any randomized control trial. Infectious diseases is one of the most serious and 
frequent complications
5)
. The effect of these immunosuppressive drugs to postoperative 
wound healing is more complicated and unclear. In our case, we successfully reduced 
antibodys and steroids with Rituximab. Eventually, enterofistura was closed, but it took 
long time to treat the liver abscess. Considering about wound healing, Rituximab 
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monotherapy could be one of the choices in the case of surgery-associated acquired 
haemophilia
12)
. However, it is insurance nonrecognition in Japan, so far we had to start
with steroids only. It took approximately one and a half months until we get the 
approval in the Institutional Review Board which was another delay of treatment. There 
is little number of cases even in the world, then RCT has been difficult to make. This 
case report could show usefulness of aPCCs and Rituximub in the treatment of acquired 
hemophilia associated with visceral surgery. 
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Figure legends 
Fig. 1 
CT and MRI showed common bile duct dilatation and obstruction at pancreatic portion. 
Fig. 2 
Prolonged aPTT was observed after preoperative cholangitis through the postoperative 
period. Infections and surgical insult may worsen acquired hemophilia. 
Immunosuppressive treatment was effective, and steroid was tapered with Rituximab. 
Fig. 3 
Subcutaneous hemorrhage was appeared with severe pain ( left panel ). After urgent 
bypassing therapy, these symptoms were vanished ( right panel ). 
Table. 1 
Initial diagnosis was established by Factor VIII deficiency (1%), when a factor VIII 
inhibitor of 8 Bethesda units was demonstrated. Factor VIII inhibitor was disappeared 
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